A First-in-Human Single and Multiple Ascending Dose Study of MT-501

Phase 1 Completed 72 enrolled Mirador Therapeutics, Inc.

RandomizedSingle-groupTriple-blindTreatment

Summary

First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) with Single and Multiple Ascending Oral Doses of MT-501 in Healthy Adults.

Timeline

Start: 2024-12-11
Primary completion: 2025-05-22
Completion: 2025-05-22

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MT-501	Unknown	—	Oral

Indications

No indication recorded.